IXICO joins the CPP Consortium

To coincide with the 2019 International Congress of Parkinson’s Disease and Movement Disorders that is taking place this week in Nice, France, IXICO is delighted to announce that it has recently joined the ground-breaking Critical Path for Parkinson’s consortium.

Created in partnership with Parkinson’s UK, one of the world’s largest charity funders of Parkinson’s research, the Critical Path for Parkinson’s Consortium (CPP) was launched in 2015. As a global collaboration to support the development of new regulatory-endorsed tools for drug development in Parkinson’s, the consortium brings together scientists from the world’s leading biopharmaceutical companies, academic institutions, government agencies, and patient-advocacy associations.

IXICO will bring to the partnership its expertise in data analytics and the regulatory qualification of biomarkers for use in clinical trials, thus supporting the consortium team’s joint endeavour to accelerate the development and validation of new drug development tools. This will provide greater insights to disease progression and improved assessment of outcomes in clinical trials for new therapies for this devastating illness.

IXICO’s CEO, Giulio Cerroni, commented, “We are delighted to join the Critical Path for Parkinson’s Consortium and to have the opportunity to contribute our scientific expertise to this global collaboration in the search for improved biomarkers to support the development of new treatments.”

As part of its work supporting the assessment of novel treatments for patients with movement disorders, IXICO is named as a co-author of a poster describing the results of changes in brain atrophy as part of the Teva sponsored Phase II LEGATO-HD study. This will be presented at the International Congress of Parkinson’s Disease and Movement Disorders (22-26th September).


Date: 26/09/2019